CCM
LNAI

Coldstream Capital Management’s Lunai Bioworks LNAI Stock Holding History

Coldstream Capital Management’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$850 – 2833
2025
Q1 		$850 Buy
+20
New +$1.28K ﹤0.01% 3226

Other funds holding LNAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Coldstream Capital Management's LNAI Position: Q2 2025 in Review

Coldstream Capital Management sold out of Lunai Bioworks (LNAI) in Q2 2025, closing a stake of 20 shares — an estimated $850 sold.

Coldstream Capital Management first reported a position in LNAI in Q1 2025 and held it in 1 quarter. The position peaked at $850 in Q1 2025. 42 funds tracked by Wall St. Rank hold LNAI as of Q2 2025.

  • Coldstream Capital Management reported no remaining Lunai Bioworks position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 20 Lunai Bioworks shares in Q2 2025, an estimated $850.
  • Coldstream Capital Management first reported a position in Lunai Bioworks in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Lunai Bioworks position peaked at $850 in Q1 2025.
  • 42 funds tracked by Wall St. Rank held Lunai Bioworks as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.